KBC Group NV Increases Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

KBC Group NV boosted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 64.0% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 25,287 shares of the medical equipment provider's stock after purchasing an additional 9,864 shares during the period. KBC Group NV's holdings in Zimmer Biomet were worth $2,730,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Intech Investment Management LLC boosted its holdings in shares of Zimmer Biomet by 22.3% in the first quarter. Intech Investment Management LLC now owns 2,177 shares of the medical equipment provider's stock valued at $287,000 after acquiring an additional 397 shares in the last quarter. O Shaughnessy Asset Management LLC lifted its stake in shares of Zimmer Biomet by 24.5% in the first quarter. O Shaughnessy Asset Management LLC now owns 23,235 shares of the medical equipment provider's stock valued at $3,067,000 after purchasing an additional 4,569 shares during the period. Seven Eight Capital LP acquired a new stake in shares of Zimmer Biomet in the first quarter valued at about $296,000. UniSuper Management Pty Ltd lifted its stake in shares of Zimmer Biomet by 381.9% in the first quarter. UniSuper Management Pty Ltd now owns 9,957 shares of the medical equipment provider's stock valued at $1,314,000 after purchasing an additional 7,891 shares during the period. Finally, Bessemer Group Inc. lifted its stake in shares of Zimmer Biomet by 13.0% in the first quarter. Bessemer Group Inc. now owns 4,220 shares of the medical equipment provider's stock valued at $557,000 after purchasing an additional 487 shares during the period. 88.89% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

ZBH has been the subject of several recent analyst reports. TD Cowen reduced their price objective on shares of Zimmer Biomet from $143.00 to $119.00 and set a "hold" rating for the company in a research note on Friday, September 6th. JPMorgan Chase & Co. cut their target price on shares of Zimmer Biomet from $125.00 to $120.00 and set a "neutral" rating for the company in a research report on Monday, September 16th. Evercore ISI cut their target price on shares of Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating for the company in a research report on Tuesday, October 1st. UBS Group cut their target price on shares of Zimmer Biomet from $112.00 to $107.00 and set a "sell" rating for the company in a research report on Thursday, August 8th. Finally, Oppenheimer cut their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an "outperform" rating for the company in a research report on Tuesday, October 15th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average target price of $123.22.

Zimmer Biomet Trading Down 1.8 %

Zimmer Biomet stock traded down $2.07 during trading on Tuesday, reaching $110.95. The company had a trading volume of 1,465,665 shares, compared to its average volume of 1,497,849. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90. The stock's 50 day moving average price is $106.45 and its two-hundred day moving average price is $109.94. The firm has a market capitalization of $22.09 billion, a price-to-earnings ratio of 21.49, a PEG ratio of 2.07 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same period in the previous year, the firm earned $1.65 earnings per share. Zimmer Biomet's revenue for the quarter was up 4.1% on a year-over-year basis. As a group, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Stockholders of record on Monday, September 30th were paid a $0.24 dividend. The ex-dividend date was Monday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.87%. Zimmer Biomet's dividend payout ratio (DPR) is presently 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.